USPTO serial 87891425
A
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 26, 2023
- Examiner
- O'BRIEN, JENNIFER LYNN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with A?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Ian W. Gillies
Ian W. Gillies KNOBBE MARTENS OLSON & BEAR LLP2040 MAIN STREET14TH FLOORIRVINE, CA 92614Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Nutraceuticals for the purpose of treating animal diseases, animal conditions and animal illnesses in the field of veterinary medicine in the nature of autoimmune disorders, oncologic disorders, renal and urinary tract disorders, neurologic disorders, musculoskeletal disorders, infectious disease disorders, dermatologic disorders, ophthalmic disorders, cardiovascular disorders, respiratory disorders, endocrine disorders, metabolic disorders including obesity, gastrointestinal disorders; Pharmaceuticals, namely, pharmaceuticals for the purpose of treating animal diseases, animal conditions and animal illnesses in the field of veterinary medicine in the nature of veterinary pharmaceutical preparations for the treatment of autoimmune disorders, oncologic disorders, renal and urinary tract disorders, neurologic disorders, musculoskeletal disorders, infectious disease disorders, dermatologic disorders, ophthalmic disorders, cardiovascular disorders, respiratory disorders, endocrine disorders, metabolic disorders including obesity, gastrointestinal disorders; Vaccines in the field of veterinary medicine; Therapeutic pharmaceuticals for the purpose of treating animal diseases, animal conditions and animal illnesses in the field of veterinary medicine in the nature of veterinary pharmaceutical preparations for the treatment of autoimmune disorders, oncologic disorders, renal and urinary tract disorders, neurologic disorders, musculoskeletal disorders, infectious disease disorders, dermatologic disorders, ophthalmic disorders, cardiovascular disorders, respiratory disorders, endocrine disorders, metabolic disorders including obesity, gastrointestinal disorders | ACTIVE | Jan 5, 2021 |
| 042 | Drug discovery services for veterinary medicine; providing pharmaceutical and medical research services and clinical, medical and scientific research information in the field of animal health; analysis services for veterinary medicine, namely, clinical, medical and scientific research; obtaining, recording, analyzing, reporting and modeling data for animal health purposes, namely, electronic monitoring and reporting of clinical information, namely, age, sex, breed, neuter status, body weight, body condition score, blood pressure, heart rate, frequency and character of respiration, appetite, presence or absence of vomiting, activity level, food and water intake, frequency and character of urination and defecation, of animals, using computers or sensors; platform as a service featuring computer software platforms and providing temporary use of non-downloadable computer software for use in database management, for use as a spreadsheet, for word processing, for statistical analysis, data aggregation, data processing, report generation, data sharing, remote data management, remote project management, and data analysis in the field of veterinary medicine for animal health purposes; platform as a service featuring computer software platforms and providing temporary use of non-downloadable computer software for assisting in drug discovery in the nature of managing clinical trials for animal health purposes; platform as a service featuring computer software platforms and providing temporary use of non-downloadable computer software to facilitate ordering and delivery of medications and treatment to animal owners, distributors and veterinary health care providers for animal health purposes | ACTIVE | Nov 13, 2018 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Anivive Lifesciences, Inc
- Other trademarks owned by Anivive Lifesciences, Inc
- Other trademarks owned by Anivive Lifesciences, Inc
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named A
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 26, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Sep 26, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 23, 2023 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Aug 22, 2023 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Jul 31, 2023 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jul 14, 2023 | IUAF | USE AMENDMENT FILED | — |
| Jul 14, 2023 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Mar 1, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 3, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 2, 2023 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Jan 26, 2023 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jan 11, 2023 | EXT5 | SOU EXTENSION 5 FILED | — |
| Jan 11, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 21, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 17, 2022 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jun 17, 2022 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jun 17, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 11, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 7, 2022 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jan 7, 2022 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jan 7, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 3, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 1, 2021 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jul 1, 2021 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jul 1, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 9, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 7, 2021 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jan 7, 2021 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jan 7, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 14, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 19, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 19, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 29, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 13, 2020 | EXPT | EXPARTE APPEAL TERMINATED | — |
| Apr 13, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 13, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 13, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 13, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 13, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 31, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 31, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 31, 2020 | ALIE | ASSIGNED TO LIE | — |
| Mar 23, 2020 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Mar 23, 2020 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| Mar 23, 2020 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Mar 23, 2020 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Sep 25, 2019 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Sep 25, 2019 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 25, 2019 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Aug 27, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 26, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 26, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 4, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 4, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 4, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 11, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 11, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 11, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 16, 2018 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Aug 16, 2018 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Aug 16, 2018 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Aug 14, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| May 4, 2018 | MDSM | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| May 3, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 27, 2018 | NWAP | NEW APPLICATION ENTERED | — |